At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 126 enrolled
Drug / intervention
Triptorelin Pamoate 11.25mgdrug
Likely dose
Triptorelin Pamoate 11.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating Triptorelin Pamoate 11.25mg for Prostate Cancer. Completed, enrolled 126 participants across 12 sites in 5 countries.
Detailed Summary
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesBulgaria, France, Latvia, Poland, Romania
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartJan 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedOct 26, 2012
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.7 years ago
Interventions
Triptorelin Pamoate 11.25mgdrug